Effects of Blood Transfusion Alone Combined with Recombinant Human Erythropoietin Injection on the Prognosis and Safety of Patients with Anemia of Hematological Malignancy

ZHANG Linhai; CHAI Xingxing; YANG Fumeng; HUO Ni; LI Qian; WANG Shan

doi:10.14009/j.issn.1672-2124.2021.04.017

您当前的位置：

首页 >

文章列表页 >

Effects of Blood Transfusion Alone Combined with Recombinant Human Erythropoietin Injection on the Prognosis and Safety of Patients with Anemia of Hematological Malignancy

更新时间：2022-10-08

- Effects of Blood Transfusion Alone Combined with Recombinant Human Erythropoietin Injection on the Prognosis and Safety of Patients with Anemia of Hematological Malignancy
- Vol. 21, Issue 4, Pages: 455-458(2021)
- 作者机构：
  
  1. 连云港市第二人民医院输血科
  2. 连云港市第二人民医院血液科
  3. 连云港市第二人民医院检验科
- 作者简介：
- 基金信息：
- DOI：10.14009/j.issn.1672-2124.2021.04.017
  CLC： R969.4
- Published：2021，
扫描看全文
[1]张林海,柴星星,杨伏猛,霍霓,李茜,王姗.单纯输血与联合重组人促红素注射液对恶性血液病贫血患者预后及安全性的影响[J].中国医院用药评价与分析,2021,21(04):455-458.

ZHANG Linhai, CHAI Xingxing, YANG Fumeng, et al. Effects of Blood Transfusion Alone Combined with Recombinant Human Erythropoietin Injection on the Prognosis and Safety of Patients with Anemia of Hematological Malignancy. [J]. 21(4):455-458(2021)
[1]张林海,柴星星,杨伏猛,霍霓,李茜,王姗.单纯输血与联合重组人促红素注射液对恶性血液病贫血患者预后及安全性的影响[J].中国医院用药评价与分析,2021,21(04):455-458. DOI： 10.14009/j.issn.1672-2124.2021.04.017.

ZHANG Linhai, CHAI Xingxing, YANG Fumeng, et al. Effects of Blood Transfusion Alone Combined with Recombinant Human Erythropoietin Injection on the Prognosis and Safety of Patients with Anemia of Hematological Malignancy. [J]. 21(4):455-458(2021) DOI： 10.14009/j.issn.1672-2124.2021.04.017.

摘要

目的:探讨单纯输血与联合重组人促红素注射液对恶性血液病贫血患者预后及安全性的影响。方法:选取2010年8月至2019年8月连云港市第二人民医院收治的240例恶性血液病贫血患者为研究对象

根据非随机临床同期对照研究及患者自愿原则分为对照组（单纯输血治疗

n=120）、观察组（在对照组基础上联合重组人促红素注射液治疗

n=120）。观察两组患者血红蛋白（Hb）、网织红细胞百分比（RET）、血清铁（Fe）、临床疗效、预后[生活质量核心问卷（quality of life questionnaire-core 30

QLQC30）评分]及药物安全性。结果:与治疗前比较

两组患者治疗后Hb、RET及Fe水平明显升高

且观察组患者的升高幅度明显大于对照组

差异均有统计学意义（P

0.05）。观察组患者的总有效率为93.33%（112/120）

明显高于对照组的83.33%（100/120）

差异有统计学意义（χ

=5.822

0.05）。观察组患者的平均治疗费用为（1 003.51±125.64）元

明显低于对照组的（1 306.25±131.66）元

差异有统计学意义（P

0.05）。治疗后1、3及5个月

观察组患者的QLQ-C30评分明显高于对照组

差异有统计学意义（P

0.05）。观察组患者的不良反应总发生率为28.33%（34/120）

较对照组的41.67%（50/120）明显更低

差异有统计学意义（χ

=4.689

0.05）。结论:与单纯输血比较

联合应用重组人促红素注射液治疗恶性血液病贫血患者的临床疗效、预后更佳

可更有效提高Hb、RET及Fe水平

且安全性更好。

Abstract

OBJECTIVE: To probe into the effect of blood transfusion alone combined with recombinant human erythropoietin injection on the prognosis and safety of patients with anemia of hematological malignancy. METHODS:240 patients with anemia of hematological malignancy admitted into the Second People’s Hospital of Lianyungang from Aug. 2010 to Aug. 2019 were selected as objects and divided into control group（ treated with blood transfusion alone

120 cases） and observation group（ treated with recombinant human erythropoietin injection on the basis of the control group

120 cases） according to the non-randomized clinical concurrent controlled study and the principle of patients’ voluntariness. The hemoglobin（ Hb）

reticulocyte percentage（ RET）

serum iron（ Fe）

clinical efficacy

prognosis[quality of life questionnaire-core 30（ QLQ-C30） score]and drug safety of the two groups were observed. RESULTS:Compared with before treatment

the Hb

RET and Fe levels of both groups had been significantly increased

and the observation group had significantly greater amplification then that of the control group

with statistically significant differences（ P

0. 05）. The total effective rate of observation group was 93. 33%（ 112/120）

which was significantly higher than that of the control group（ 83. 33%

100/120）

with statistically significant difference（ χ

= 5. 822

0. 05）. The average treatment expense of observation group was（ 1 003. 51 ± 125. 64） yuan

which was significantly lower than that of the control group [（ 1 306. 25 ± 131. 66） yuan]

with statistically significant difference（ P

0. 05）. At 1

3 and 5 months after treatment

the QLQ-C30 score of observation group was significantly higher than that of the control group

with statistically significant difference（ P

0. 05）. The incidence of adverse drug reactions of observation group was 28. 33%（ 34/120）

which was significantly lower than that of the control group（ 41. 67%

50/120）

with statistically significant difference（ χ

= 4. 689

0. 05）. CONCLUSIONS: Compared with blood transfusion alone

the recombinant human erythropoietin injection has better clinical efficacy and prognosis in the treatment of patients with anemia of hematological malignancy

which may be related to the recombinant human erythropoietin injection has better effect in improving Hb

RET and Fe levels

and with higher safety..

关键词

恶性血液病贫血单纯输血重组人促红素注射液预后

Keywords

Hematologic malignancyAnemiaBlood transfusion aloneRecombinant human erythropoietin injectionPrognosis

references

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Prognosis and Safety of Programmed Death 1 Inhibitors in First-Line Treatment of Advanced Non-Small Cell Lung Cancer

Effects of Modified Chaihu Shugan Powder Combined with Antiviral Drugs on Prognosis of Patients with Chronic Hepatitis B

Efficacy of Losartan Combined with Oral Iron Preparation in the Treatment of Elderly Chronic Kidney Disease Complicated with Anemia and Its Effect on Hemoglobin Level

Effect of Qingwei Xiehuo Recipe Combined with Tinidazole-Assisted Root Canal Filling on Periodontal Micro-Ecological Environment,Inflammatory Factor Levels in Gingival Crevicular Fluid and Prognosis in Patients with Combined Periodontal-Endodontic Lesions

Effects of Antiplatelet Drugs Therapy Guided by Platelet Aggregation Rate on the Short-Term and Long-Term Prognosis in Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention

Related Author

FANG Ping

WANG Genhe

ZUO Gang

LI Jiao

HUO Ruijing

LI Jing

ZHANG Cuili

ZHAO Qing

Related Institution

Dept. of Oncology, Huangshan People’s Hospital

Dept.of Emergency, Shijiazhuang Maternity ＆ Child Healthcare Hospital

Dept.of Manufacturing Laboratory, Shijiazhuang Traditional Chinese Medicine Hospital

Dept.of Gastroenterology, Xingtai Peolpe’s Hospital

Dept.of Internal Medicine, Shijiazhuang Maternity ＆ Child Healthcare Hospital

⁰